Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bosentan for cerebral hypoperfusion in relapsing-remitting multiple sclerosis
2017-001253-13Phase 2Completed
- Sponsor
- UZ Brussel
- Start
- Jul 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in multiple sclerosis (MS) comparing Bosentan with Placebo (2 arms). Primary endpoint: N-acetyl aspartate levels after restoration of cerebral blood flow. Started Jul 2017; status: completed.
02
Drugs
bosentan
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2017-001253-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001253-13.